SMH
UNCY icon

Sanders Morris Harris’s Unicycive Therapeutics UNCY Stock Holding History

Sanders Morris Harris’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$57K – 354
2021
Q3 		$57K Buy
+2,000
New +$57.4K 0.01% 306

Other funds holding UNCY

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tandem Capital Management Woodcliff Lake, New Jersey $200M AUM 25.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sanders Morris Harris's UNCY Position: Q4 2021 in Review

Sanders Morris Harris sold out of Unicycive Therapeutics (UNCY) in Q4 2021, closing a stake of 2,000 shares — an estimated $57K sold.

Sanders Morris Harris first reported a position in UNCY in Q3 2021 and held it in 1 quarter. The position peaked at $57K in Q3 2021. 11 funds tracked by Wall St. Rank hold UNCY as of Q4 2021.

  • Sanders Morris Harris reported no remaining Unicycive Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Sanders Morris Harris sold 2,000 Unicycive Therapeutics shares in Q4 2021, an estimated $57K.
  • Sanders Morris Harris first reported a position in Unicycive Therapeutics in Q3 2021 and held it in 1 quarter.
  • Sanders Morris Harris's Unicycive Therapeutics position peaked at $57K in Q3 2021.
  • 11 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q4 2021.

Based on Sanders Morris Harris's 13F filing for Q4 2021, filed 2 Feb 2022.